Worth reading
28Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateKey initiatives
01Establishing a stable earnings base through the biosimilars business
02New initiatives for further growth: development of new biosimilars and the CDMO business
03Establishing a commercialization framework in Japan and overseas to achieve early growth
04Recruitment and development of human resources; sustainability initiatives
05Business Portfolio
Plan assumptionsForecast CAGR for the global biosimilars market: 14.74%, Drug development period: 9–17 years, The global allogeneic stem cell market is forecast to reach ¥2.0193 trillion in 2040
Size of the Target MarketBiosimilars market size Not disclosed / growth_rate CAGR：14.74％ / source GLOBAL BIOSIMILAR MARKET RESEARCH REPORT / Allogeneic stem cell market size 2040: ¥2.0193 trillion (global) / growth_rate Not disclosed / source Japan Agency for Medical Research and Development website, FY2019 Market Survey of Regenerative Medicine and Gene Therapy: Final Report; GlobalData; epidemiological literature; rare disease information websites; and other sources / Target patient population for cerebral palsy size Japan: 78,000 patients, including 24,000 under the age of 18; Japan, the United States and Europe: 240,000 pediatric patients aged 10 or younger / growth_rate Incidence: 1 in approximately 500 births / source Figures published by the Cabinet Office and estimates by GlobalData
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Progress against the plan | Annual update |
| Plan assumptions | Forecast CAGR for the global biosimilars market: 14.74%, Drug development period: 9–17 years, The global allogeneic stem cell market is forecast to reach ¥2.0193 trillion in 2040 |
| Key initiatives | Establishing a stable earnings base through the biosimilars business, New initiatives for further growth: development of new biosimilars and the CDMO business, Establishing a commercialization framework in Japan and overseas to achieve early growth, Recruitment and development of human resources; sustainability initiatives, Business Portfolio |
| Size of the Target Market | Biosimilars market size Not disclosed / growth_rate CAGR：14.74％ / source GLOBAL BIOSIMILAR MARKET RESEARCH REPORT / Allogeneic stem cell market size 2040: ¥2.0193 trillion (global) / growth_rate Not disclosed / source Japan Agency for Medical Research and Development website, FY2019 Market Survey of Regenerative Medicine and Gene Therapy: Final Report; GlobalData; epidemiological literature; rare disease information websites; and other sources / Target patient population for cerebral palsy size Japan: 78,000 patients, including 24,000 under the age of 18; Japan, the United States and Europe: 240,000 pediatric patients aged 10 or younger / growth_rate Incidence: 1 in approximately 500 births / source Figures published by the Cabinet Office and estimates by GlobalData |
| Publication date | 30 June 2026 |
Items this document does not state (19)
Plan periodSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsResults under the previous planReason for revision or withdrawalRisks identifiedDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To establish a stable earnings base through the biosimilars business while pursuing the eradication of pediatric and rare diseases and rapid growth through the cell therapy business, thereby achieving both “strengthening the earnings base by achieving operating profitability” and “steadily executing R&D investments focused on future growth opportunities.”
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.